In­dus­try lead­ers warn that abor­tion pill rul­ing puts FDA in 'to­tal­ly un­chart­ed ter­ri­to­ry'

In­dus­try lead­ers warned that a Texas court’s re­cent rul­ing to sus­pend a med­ica­tion abor­tion drug’s decades-long ap­proval sets a dan­ger­ous prece­dent for the FDA’s reg­u­la­to­ry pow­er.

More than half of women who choose to end their preg­nan­cies re­ly on mifepri­s­tone, ac­cord­ing to re­cent­ly filed court doc­u­ments, in­clud­ing more than 5 mil­lion Amer­i­cans over the last two decades. How­ev­er, un­less a stay is grant­ed on the Texas de­ci­sion, providers and phar­ma­cies have just un­til the end of this week to pur­chase mifepri­s­tone, ac­cord­ing to a spokesper­son from Dan­co Lab­o­ra­to­ries, mak­er of the brand-name Mifeprex.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER